Antimicrobial therapy for methicillin-resistant Staphylococcus aureus
- Authors
- Choo, Eun Ju
- Issue Date
- Mar-2018
- Publisher
- 대한의사협회
- Keywords
- Methicillin-resistant; Staphylococcus aureus; Vancomycin; Treatment
- Citation
- 대한의사협회지, v.61, no.3, pp 207 - 213
- Pages
- 7
- Journal Title
- 대한의사협회지
- Volume
- 61
- Number
- 3
- Start Page
- 207
- End Page
- 213
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6172
- DOI
- 10.5124/jkma.2018.61.3.207
- ISSN
- 1975-8456
2093-5951
- Abstract
- Methicillin-resistant Staphylococcus aureus (MRSA) is a common cause of healthcare-associated infections. Recently, community-associated MRSA has emerged, manifesting as skin and soft tissue infections in patients without any prior healthcare contact. Vancomycin, a glycopeptide in clinical use for more than 50 years, still remains an acceptable treatment option. However, significant concerns have been raised regarding the decreasing susceptibility of S. aureus to this agent. The growing awareness of the limitations of vancomycin has served as an impetus for development of newer agents. There has been an increase in the number of agents available to treat MRSA infections. Linezolid, daptomycin, telavancin, and ceftaroline have received regulatory approval in the last decade for the treatment of MRSA. Although these drugs do have certain differentiating attributes and may offer some advantages over vancomycin, they also have significant limitations.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/6172)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.